Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B

Harmony Biosciences Holdings, Inc.

Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.
Glenn Reicin appointed CFO; previously CFO at Eccogene and Alladapt, Managing Director at Skyline Ventures.
New CFO: $500K base salary, 50% target bonus, $3M option grant vesting over four years.
Company reiterates 2026 net product revenue guidance of $1.0-$1.04 billion from WAKIX sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.